Jiajia Jin1, Ping Zhan2, Masaru Katoh3, Susumu S Kobayashi4, Kevin Phan5, Hong Qian1, Huijuan Li6, Xiaoxia Wang7, Xihua Wang8, Yong Song2. 1. Department of Respiratory Medicine, Nanjing General Hospital of Nanjing Military Command, Southeast University, Nanjing 210009, China. 2. Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China. 3. Department of Omics Network, National Cancer Center, Tokyo 1040045, Japan. 4. Lung Cancer Research Program, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston 02215, USA. 5. The Collaborative Research (CORE) Group, Macquarie University, Sydney, Australia. 6. Nanjing Medical University, Nanjing 210009, China. 7. Intensive Care Unit, Inner Mongolia People's Hospital, Hohhot 010017, China. 8. Department of Respiratory Medicine, Zhongda Hospital, Medical School of Southeast University, Nanjing 210009, China.
Abstract
BACKGROUND: β-catenin is a key component of the canonical Wnt pathway, which plays pivotal roles in malignant transformation and cancer progression. Several studies have reported the clinical significance of the expression level of β-catenin in different subcellular locations. This meta-analysis aimed to assess the prognostic value of β-catenin expression patterns in patients with non-small cell lung cancer (NSCLC). METHODS: PubMed and Embase databases were searched to identify all articles referring to the association between β-catenin expression level and outcomes of patients of NSCLC up to November 2016. We included eligible studies to summarize the extracted data in terms of pooled hazard ratios (HRs) and their 95% confidence intervals (95% CIs). RESULTS: A total of 24 studies published between 2000 and 2016 were eligible for this meta-analysis. The total number of patients with NSCLC included was 2,807. Pooled HRs and 95% CIs suggested that positive β-catenin expression in membrane was associated with higher survival rates (HR: 0.53; 95% CI: 0.32-0.87), whereas β-catenin expression in cytoplasm and nucleus had unfavorable impacts on survival rates with HR of 1.63 (95% CI: 1.34-1.99) and HR of 3.15 (95% CI: 1.97-5.05), respectively. But, there was no significant association between β-catenin expression in abnormal pattern with prognosis (HR: 1.38; 95% CI: 0.61-3.15). Publication bias was absent in all of the four outcomes. Sensitivity analysis revealed that the results of this meta-analysis were robust. CONCLUSIONS: Reduced membranous β-catenin, positive expression of cytoplasmic or nuclear β-catenin is all correlated with poor prognosis, although we did not identify a significant association between abnormal β-catenin expression and clinical outcome of NSCLC patients. The meta-analysis suggested that membranous, cytoplasmic and nuclear β-catenin all could serve as an important prognosticator for patients with NSCLC.
BACKGROUND: β-catenin is a key component of the canonical Wnt pathway, which plays pivotal roles in malignant transformation and cancer progression. Several studies have reported the clinical significance of the expression level of β-catenin in different subcellular locations. This meta-analysis aimed to assess the prognostic value of β-catenin expression patterns in patients with non-small cell lung cancer (NSCLC). METHODS: PubMed and Embase databases were searched to identify all articles referring to the association between β-catenin expression level and outcomes of patients of NSCLC up to November 2016. We included eligible studies to summarize the extracted data in terms of pooled hazard ratios (HRs) and their 95% confidence intervals (95% CIs). RESULTS: A total of 24 studies published between 2000 and 2016 were eligible for this meta-analysis. The total number of patients with NSCLC included was 2,807. Pooled HRs and 95% CIs suggested that positive β-catenin expression in membrane was associated with higher survival rates (HR: 0.53; 95% CI: 0.32-0.87), whereas β-catenin expression in cytoplasm and nucleus had unfavorable impacts on survival rates with HR of 1.63 (95% CI: 1.34-1.99) and HR of 3.15 (95% CI: 1.97-5.05), respectively. But, there was no significant association between β-catenin expression in abnormal pattern with prognosis (HR: 1.38; 95% CI: 0.61-3.15). Publication bias was absent in all of the four outcomes. Sensitivity analysis revealed that the results of this meta-analysis were robust. CONCLUSIONS: Reduced membranous β-catenin, positive expression of cytoplasmic or nuclear β-catenin is all correlated with poor prognosis, although we did not identify a significant association between abnormal β-catenin expression and clinical outcome of NSCLCpatients. The meta-analysis suggested that membranous, cytoplasmic and nuclear β-catenin all could serve as an important prognosticator for patients with NSCLC.
Authors: A Bleckmann; L Siam; F Klemm; E Rietkötter; Chr Wegner; F Kramer; T Beissbarth; C Binder; Chr Stadelmann; T Pukrop Journal: Clin Exp Metastasis Date: 2012-12-08 Impact factor: 5.150
Authors: Christina C Pierre; Shawn M Hercules; Clayton Yates; Juliet M Daniel Journal: Biochim Biophys Acta Rev Cancer Date: 2018-11-09 Impact factor: 11.414
Authors: Jun Sang Bae; Sang Jae Noh; Kyoung Min Kim; See-Hyoung Park; Usama Khamis Hussein; Ho Sung Park; Byung-Hyun Park; Sang Hoon Ha; Ho Lee; Myoung Ja Chung; Woo Sung Moon; Dong Hyu Cho; Kyu Yun Jang Journal: Front Oncol Date: 2018-11-20 Impact factor: 6.244
Authors: Shuangyi Cai; Thomas Hu; Mythreye Venkatesan; Mayar Allam; Frank Schneider; Suresh S Ramalingam; Shi-Yong Sun; Ahmet F Coskun Journal: iScience Date: 2022-08-18
Authors: Susan Park; Manali Vora; Annemieke van Zante; Joseph Humtsoe; Hyun-Su Kim; Sue Yom; Shweta Agarwal; Patrick Ha Journal: J Otolaryngol Head Neck Surg Date: 2020-07-10
Authors: Poonam Sarode; Xiang Zheng; Georgia A Giotopoulou; Andreas Weigert; Carste Kuenne; Stefan Günther; Aleksandra Friedrich; Stefan Gattenlöhner; Thorsten Stiewe; Bernhard Brüne; Friedrich Grimminger; Georgios T Stathopoulos; Soni Savai Pullamsetti; Werner Seeger; Rajkumar Savai Journal: Sci Adv Date: 2020-06-05 Impact factor: 14.136